JP2024542523A5 - - Google Patents

Info

Publication number
JP2024542523A5
JP2024542523A5 JP2024530556A JP2024530556A JP2024542523A5 JP 2024542523 A5 JP2024542523 A5 JP 2024542523A5 JP 2024530556 A JP2024530556 A JP 2024530556A JP 2024530556 A JP2024530556 A JP 2024530556A JP 2024542523 A5 JP2024542523 A5 JP 2024542523A5
Authority
JP
Japan
Prior art keywords
weeks
approximately
gene
disease
neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024530556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542523A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/050940 external-priority patent/WO2023097029A1/en
Publication of JP2024542523A publication Critical patent/JP2024542523A/ja
Publication of JP2024542523A5 publication Critical patent/JP2024542523A5/ja
Pending legal-status Critical Current

Links

JP2024530556A 2021-11-23 2022-11-23 神経変性障害の治療選択及び治療 Pending JP2024542523A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163282615P 2021-11-23 2021-11-23
US63/282,615 2021-11-23
US202263393573P 2022-07-29 2022-07-29
US63/393,573 2022-07-29
PCT/US2022/050940 WO2023097029A1 (en) 2021-11-23 2022-11-23 Therapy selection and treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
JP2024542523A JP2024542523A (ja) 2024-11-15
JP2024542523A5 true JP2024542523A5 (cg-RX-API-DMAC10.html) 2025-12-03

Family

ID=86540341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024530556A Pending JP2024542523A (ja) 2021-11-23 2022-11-23 神経変性障害の治療選択及び治療

Country Status (6)

Country Link
US (1) US20240417798A1 (cg-RX-API-DMAC10.html)
EP (1) EP4436573A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024542523A (cg-RX-API-DMAC10.html)
AU (1) AU2022396274A1 (cg-RX-API-DMAC10.html)
CA (1) CA3237579A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023097029A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122374019A (zh) * 2023-09-08 2026-07-10 阿纳韦克斯生命科学公司 脑萎缩的治疗和预防
WO2025117826A1 (en) * 2023-11-30 2025-06-05 Anavex Life Sciences Corp. Methods of using surrogate biomarkers in sigma-1 receptor therapy
CN117679516A (zh) * 2023-12-13 2024-03-12 广东工业大学 Ndufa7基因在制备改善和/或治疗线粒体功能障碍相关疾病的药物中的应用
WO2025231180A1 (en) * 2024-05-01 2025-11-06 Anavex Life Sciences Corp. Blarcamesine correction of eeg biomarkers in fragile x syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476103B1 (en) * 2005-10-17 2009-01-13 Penelope Anne Norman Science party kit and method
CN106501251A (zh) * 2016-12-09 2017-03-15 防城港市质量技术监督局 一种用于检测大麻油的试剂盒
US20200338045A1 (en) * 2017-11-01 2020-10-29 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
US12383526B2 (en) * 2018-05-18 2025-08-12 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
WO2020018461A1 (en) * 2018-07-16 2020-01-23 The University Of Virginia Patent Foundation Compositions and methods of diagnosis and treatment for neurological diseases

Similar Documents

Publication Publication Date Title
Reif et al. Precision medicine in genetic epilepsies: break of dawn?
Plecko et al. Pipecolic acid elevation in plasma and cerebrospinal fluid of two patients with pyridoxine‐dependent epilepsy
JP2002507564A (ja) βアミロイドタンパク質を減少させるための方法
Meda et al. Genetic interactions associated with 12-month atrophy in hippocampus and entorhinal cortex in Alzheimer's Disease Neuroimaging Initiative
JP7347743B2 (ja) トラジピタントによるアトピー性皮膚炎の改善された治療
Ebner et al. Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference
JP2012511154A (ja) 生体分子の濃度を測定するための方法
TW202308635A (zh) 治療與監測帕金森氏病之方法
Bame et al. Amino Acids as biomarkers in the SOD1G93A mouse model of ALS
JP5713887B2 (ja) 筋変性疾患の検出方法、及び治療効果判定方法
WO2024074133A1 (en) Protein marker for assessing and treating neurodegenerative diseases
US20170248586A1 (en) Marker For Depression, Assay Method, Method For Determining Depression, Screening Method For Antidepressants, And Kit
Liu et al. circ0066187 promotes pulmonary fibrogenesis through targeting STAT3-mediated metabolism signal pathway
CN103547289A (zh) 治疗阿尔茨海默氏病的方法和组合物
Asai et al. Status epilepticus decreases brain cytochrome P450 2D4 expression in rats
CN119856057A (zh) 用于监测共济蛋白替代疗法的共济蛋白敏感性脂质标志物
Reynolds The neurochemistry of schizophrenia
US20130196980A1 (en) Diagnostic agent, diagnostic method and therapeutic agent for fibromyalgia
US11406613B2 (en) Treatment of osteoarthritis
EP2389589B1 (en) Methods of diagnosing and treating multiple sclerosis
Yanping et al. Yinxie I Formula attenuates imiquimod-induced psoriasis-like skin inflammation via IL-23/IL-17 axis
JP2020153742A (ja) 進行期非扁平上皮肺癌患者の化学療法反応性を評価するための情報を提供する方法
Chen et al. Pterostilbene targets microglia-mediated neuroinflammation for Alzheimer therapy
WO2010105189A1 (en) Method for identifying compounds that attenuate the function or reduce abundance of a voltage-gated potassium channel and are associated with maintenance of cognitive function in old age
WO2018137028A1 (en) Methods, compositions and kits for assessing brain inflammation in depression and related conditions